Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC002 CAR-T in CLDN18.2-positive gastric cancer
NCT07103668Phase 3Recruiting
- Sponsor
- Immunofoco
- Start
- Aug 2025
- Primary completion
- May 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of claudin 18.2 CAR-T in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Immunofoco. Started Aug 2025; status: recruiting.
02
Drugs
claudin 18.2 CAR-T
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07103668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07103668.